Connection

Kit Simpson to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Kit Simpson has written about Cost-Benefit Analysis.
Kit Simpson
Connection Strength
2.952
Cost-Benefit Analysis
  1. Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One. 2014; 9(5):e98152.
    View in: PubMed
    Score: 0.398
  2. Measuring Value: Cost-Effectiveness Analysis for Occupational Therapy. Am J Occup Ther. 2022 Jan 01; 76(1).
    View in: PubMed
    Score: 0.168
  3. Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain. J Comp Eff Res. 2021 10; 10(15):1107-1119.
    View in: PubMed
    Score: 0.163
  4. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998 Jul; 4(7):1004-12.
    View in: PubMed
    Score: 0.132
  5. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
    View in: PubMed
    Score: 0.122
  6. Design and assessment of cost-effectiveness studies in AIDS populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 4:S28-32.
    View in: PubMed
    Score: 0.104
  7. Cost-effectiveness analysis of annual Trichomonas vaginalis screening and treatment in HIV-positive women to prevent HIV transmission. Sex Transm Dis. 2014 Jun; 41(6):353-8.
    View in: PubMed
    Score: 0.099
  8. Cost-effectiveness analysis of 2 surveillance options for cervical intraepithelial neoplasia 1. J Low Genit Tract Dis. 2014 Apr; 18(2):136-41.
    View in: PubMed
    Score: 0.098
  9. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol. 2013 Sep; 122(3):579-85.
    View in: PubMed
    Score: 0.094
  10. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.
    View in: PubMed
    Score: 0.092
  11. The cost of Medicaid savings: the potential detrimental public health impact of neonatal circumcision defunding. Infect Dis Obstet Gynecol. 2012; 2012:540295.
    View in: PubMed
    Score: 0.089
  12. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. J Low Genit Tract Dis. 2012 Jul; 16(3):275-80.
    View in: PubMed
    Score: 0.087
  13. A cost-effectiveness analysis of inhaled corticosteroid delivery for children with asthma in the emergency department. J Pediatr. 2012 Nov; 161(5):903-7.
    View in: PubMed
    Score: 0.087
  14. Economic analysis of secondary trial data. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):351-6.
    View in: PubMed
    Score: 0.084
  15. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
    View in: PubMed
    Score: 0.083
  16. Timing of elective repeat cesarean delivery at term and neonatal outcomes: a cost analysis. Am J Obstet Gynecol. 2010 Jun; 202(6):632.e1-6.
    View in: PubMed
    Score: 0.075
  17. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009 Mar; 26(3):346-68.
    View in: PubMed
    Score: 0.069
  18. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.069
  19. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009; 27(2):159-65.
    View in: PubMed
    Score: 0.068
  20. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37.
    View in: PubMed
    Score: 0.066
  21. Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. J Hosp Med. 2008 Mar; 3(2):134-41.
    View in: PubMed
    Score: 0.065
  22. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Investig. 2007; 27(1):67-74.
    View in: PubMed
    Score: 0.060
  23. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007; 27(12):807-17.
    View in: PubMed
    Score: 0.060
  24. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5(5):294-304.
    View in: PubMed
    Score: 0.051
  25. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004 Jun; 9(6):476-82.
    View in: PubMed
    Score: 0.050
  26. COVID-19 Pandemic and Beyond: Considerations and Costs of Telehealth Exercise Programs for Older Adults With Functional Impairments Living at Home-Lessons Learned From a Pilot Case Study. Phys Ther. 2020 08 12; 100(8):1278-1288.
    View in: PubMed
    Score: 0.038
  27. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine. Value Health. 2000 May-Jun; 3(3):186-201.
    View in: PubMed
    Score: 0.037
  28. Cost-effectiveness evaluation of the PROPPR trial transfusion protocols. Transfusion. 2020 05; 60(5):922-931.
    View in: PubMed
    Score: 0.037
  29. Health economics in HIV disease. A review of the European literature. Pharmacoeconomics. 1999; 15 Suppl 1:1-12.
    View in: PubMed
    Score: 0.034
  30. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998 Feb; 91(2):174-81.
    View in: PubMed
    Score: 0.032
  31. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997 Jul; 12(1):54-66.
    View in: PubMed
    Score: 0.031
  32. Is POCT cost effective for coronary bypass patients in ICUs? MLO Med Lab Obs. 1996 Feb; 28(2):58-62.
    View in: PubMed
    Score: 0.028
  33. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics. 1994 Dec; 6(6):553-62.
    View in: PubMed
    Score: 0.026
  34. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
    View in: PubMed
    Score: 0.024
  35. Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstet Gynecol. 2011 Sep; 118(3):655-662.
    View in: PubMed
    Score: 0.021
  36. Informing the mammography coverage debate. Results of meta-analysis, computer modeling, and issue analysis. Int J Technol Assess Health Care. 1991; 7(4):616-31.
    View in: PubMed
    Score: 0.020
  37. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009; 29(10):635-46.
    View in: PubMed
    Score: 0.017
  38. Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke. 2008 May; 3(2):138-44.
    View in: PubMed
    Score: 0.016
  39. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
    View in: PubMed
    Score: 0.016
  40. The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios. Pharmacoeconomics. 2004; 22(18):1209-16.
    View in: PubMed
    Score: 0.012
  41. Economic decision analysis model of screening for lung cancer. Eur J Cancer. 2001 Sep; 37(14):1759-67.
    View in: PubMed
    Score: 0.010
  42. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000 Nov; 95(11):3250-8.
    View in: PubMed
    Score: 0.010
  43. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.